Goldenwell Biotech, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -38.8% | -38.8% | -25.4% |
| FY2022 | -488.6% | -488.6% | -396.6% |
| FY2023 | -139.3% | -89.9% | -51.5% |
| FY2024 | 278.4% | -103.8% | -58.7% |
| FY2025 | 86.3% | 86.3% | -820.8% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -38.8% | -38.8% | -25.4% |
| FY2022 | -488.6% | -488.6% | -396.6% |
| FY2023 | -139.3% | -89.9% | -51.5% |
| FY2024 | 278.4% | -103.8% | -58.7% |
| FY2025 | 86.3% | 86.3% | -820.8% |